【Company Research】WuXi Biologics (2269 HK) – Growth momentum intact |
【Company Research】Tencent (700 HK) – Looking into 2H22E recovery |
【Company Research】InnoCare Pharma (9969 HK) – A successful commercial year for orelabrutinib |
【Company Research】Sunny Optical (2382 HK) – Headwinds to persist into 1H22E; Maintain HOLD |
【Company Research】Tongcheng-Elong (780 HK) – Looking beyond 3M22E epidemic |
【Company Research】Anta Sports (2020 HK) – A mixed guidance but long-term growth intact |
【Company Research】GDS (9698 HK) – Remains committed in tier-one cities resources |
【Company Research】GDS (GDS US) – Remains committed in tier-one cities resources |
【Company Research】CSPC Pharmaceutical (1093 HK) – Promising early data of COVID-19 mRNA vaccine |
【Company Research】Sunny Optical (2382 HK) – 2H21 first take: worse-than-expected GPM pressure |